U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H30N6O6
Molecular Weight 558.5862
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLMESARTAN MEDOXOMIL

SMILES

CCCc1nc(c(C(=O)OCc2c(C)oc(=O)o2)n1Cc3ccc(cc3)-c4ccccc4-c5n[nH]nn5)C(C)(C)O

InChI

InChIKey=UQGKUQLKSCSZGY-UHFFFAOYSA-N
InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021286s023lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/19033634 https://www.ncbi.nlm.nih.gov/pubmed/12076183

Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension, this dosage has consistently helped achieve a double-digit reduction both in systolic and diastolic blood pressure, a reduction which is maintained for one year. Extensive clinical evidence from several large well designed trials and the clinical practice setting has confirmed the antihypertensive efficacy and good tolerability profile of oral olmesartan medoxomil, as monotherapy in patients with hypertension. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo.

CNS Activity

Curator's Comment:: Olmesartan in a dose dependent manner showed increase in antiepileptic activity toward chemically induced seizure model in mice. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.091 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BENICAR

Approved Use

Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.

Launch Date

1.01969278E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2204 ng/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OLMESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5975 ng × h/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OLMESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.5 h
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OLMESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 65-75 years
n = 12
Health Status: unhealthy
Condition: hypertension
Age Group: 65-75 years
Sex: M+F
Population Size: 12
Sources:
320 mg single, oral
Highest studied dose
Dose: 320 mg
Route: oral
Route: single
Dose: 320 mg
Sources:
healthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
weak [Inhibition 10 uM]
weak [Inhibition 500 uM]
weak [Inhibition 500 uM]
weak [Inhibition 500 uM]
weak [Inhibition 500 uM]
weak [Inhibition 500 uM]
weak [Inhibition 500 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.
2003 Jan
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
2004
Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.
2004 Jul
Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent.
2005 Aug 11
Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan.
2007 May
Patents

Sample Use Guides

BENICAR (olmesartan med oxomil) tablets dosage. Adult hypertension: Starting dose - 20 mg once daily (dose range 20 - 40 mg once daily). Pediatric hypertension (6 - 16 years): Starting dose for patients with body weight 20 to <35 kg - 10 mg once daily, if body weight >35 kg - 20 mg once daily (dose range 10 - 20 mg once daily and 20 - 40 mg once daily, respectively)
Route of Administration: Oral
Pre-treatment with 100 nM olmesartan abolished Ang II-induced apoptosis in cultured mouse podocytes
Name Type Language
OLMESARTAN MEDOXOMIL
INN   JAN   MART.   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OLMESARTAN MEDOXOMIL COMPONENT OF TRIBENZOR
Brand Name English
OLMESARTAN MEDOXOMIL [ORANGE BOOK]
Common Name English
AZOR COMPONENT OLMESARTAN MEDOXOMIL
Common Name English
NSC-758924
Code English
OLMESARTAN MEDOXOMIL [USP-RS]
Common Name English
OLMESARTAN MEDOXOMIL [INN]
Common Name English
OLMESARTAN MEDOXOMIL [VANDF]
Common Name English
BENICAR
Brand Name English
OLMESARTAN MEDOXOMIL COMPONENT OF BENICAR HCT
Common Name English
OLMESARTAN MEDOXOMIL [USP MONOGRAPH]
Common Name English
OLMESARTAN MEDOXOMIL [EP MONOGRAPH]
Common Name English
CS-866
Code English
OLMESARTAN MEDOXOMIL [JAN]
Common Name English
OLMESARTAN MEDOXOMIL [USAN]
Common Name English
OLMESARTAN MEDOXOMIL [MART.]
Common Name English
BENICAR HCT COMPONENT OLMESARTAN MEDOXOMIL
Common Name English
1H-IMIDAZOLE-5-CARBOXYLIC ACID, 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, (5-METHYL-2-OXO-1,3- DIOXOL-4-YL)METHYL ESTER
Common Name English
OLMESARTAN MEDOXOMIL [WHO-DD]
Common Name English
OLMESARTAN MEDOXOMIL COMPONENT OF AZOR
Common Name English
OLMETEC
Brand Name English
TRIBENZOR COMPONENT OLMESARTAN MEDOXOMIL
Brand Name English
Classification Tree Code System Code
WHO-ATC C09DA08
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-ATC C09DX03
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-ATC C09CA08
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
NCI_THESAURUS C66930
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-VATC QC09CA08
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-VATC QC09DB02
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-VATC QC09DA08
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
WHO-ATC C09DB02
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
Code System Code Type Description
MESH
C097933
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
DRUG CENTRAL
1985
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
PUBCHEM
130881
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200692
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
FDA UNII
6M97XTV3HD
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
EPA CompTox
144689-63-4
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
MERCK INDEX
M8203
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
RXCUI
118463
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1478367
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C47640
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
CAS
144689-63-4
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
INN
7787
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
DRUG BANK
DB00275
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY
EVMPD
SUB03508MIG
Created by admin on Fri Jun 25 21:07:39 UTC 2021 , Edited by admin on Fri Jun 25 21:07:39 UTC 2021
PRIMARY